Madrigal Pharmaceuticals Inc [MDGL] stock is trading at $259.34, up 20.10%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MDGL shares have gain 27.76% over the last week, with a monthly amount glided 24.00%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Wolfe Research started tracking the stock with Outperform rating on June 11, 2024, and set its price target to $382. On April 22, 2024, BofA Securities initiated with a Underperform rating and assigned a price target of $150 on the stock. B. Riley Securities upgraded its rating to a Neutral and increased its price target to $270 on March 15, 2024. Citigroup initiated its recommendation with a Buy and recommended $382 as its price target on March 06, 2024. B. Riley Securities downgraded its rating to Sell for this stock on February 26, 2024, but kept the price target unchanged to $155. In a note dated December 20, 2022, Oppenheimer reiterated an Outperform rating on this stock and boosted its target price from $170 to $250.
Madrigal Pharmaceuticals Inc [MDGL] stock has fluctuated between $125.57 and $299.98 over the past year. Currently, Wall Street analysts expect the stock to reach $315.75 within the next 12 months. Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] shares were valued at $259.34 at the most recent close of the market. An investor can expect a potential return of 21.75% based on the average MDGL price forecast.
Analyzing the MDGL fundamentals
Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -7.06%, Pretax Profit Margin comes in at -6.69%, and Net Profit Margin reading is -6.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.72 and Total Capital is -0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 243.74 points at the first support level, and at 228.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 269.24, and for the 2nd resistance point, it is at 279.14.
Ratios To Look Out For
For context, Madrigal Pharmaceuticals Inc’s Current Ratio is 8.72. As well, the Quick Ratio is 8.67, while the Cash Ratio is 1.31. Considering the valuation of this stock, the price to sales ratio is 384.63, the price to book ratio is 6.01.
Transactions by insiders
Recent insider trading involved Sibold William John, President and CEO, that happened on Sep 09 ’24 when 6363.0 shares were sold. Officer, William John Sibold completed a deal on Sep 09 ’24 to buy 6363.0 shares. Meanwhile, Senior VP, Chief Pharma Dev. Waltermire Robert E. sold 1900.0 shares on Jun 14 ’24.
